Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:37:39 2024-04-19 am EDT			5-day change	1st Jan Change
86.89 ^EUR	+1.95%		+0.49%	-3.20%

Apr. 19	Sector Update: Health Care Stocks Rise Friday Afternoon	MT
Apr. 19	Global markets live: P&G, Amex, Blackstone, Apple, Tesla...

SANOFI : UBS reiterates its Neutral rating

October 28, 2022 at 10:54 am EDT

Michael Leuchten from UBS retains his Neutral opinion on the stock. The target price continues to be set at EUR 103.

Latest news about Sanofi

Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Global markets live: P&G, Amex, Blackstone, Apple, Tesla...	Apr. 19
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Sanofi Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	Apr. 19	MT
Sanofi Reportedly Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	Apr. 18	MT
Sanofi to overhaul US operations of vaccines, cut jobs	Apr. 18	RE
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
SANOFI : JP Morgan reiterates its Neutral rating	Apr. 18	ZD
Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger	Apr. 18	CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	Apr. 17	MT
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Sanofi's Frexalimab Reduces Disease Activity in Multiple Sclerosis Patients in Phase 2 Trial	Apr. 17	MT
Sanofi: new positive phase II results in MS	Apr. 17	CF
IDT Australia Signs Master Service Agreement with Sanofi	Apr. 15	MT
Sanofi: progress in hematology trial	Apr. 15	CF
Innate Pharma: progress in hematology trial	Apr. 15	CF
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	Apr. 12	DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	Apr. 12	MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts	Apr. 12	RE
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	Apr. 09	DJ
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	Apr. 09	MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	Apr. 09	CI
Sanofi Launches Rabies Vaccine in the UK	Apr. 05	MT
Sanofi: rabies vaccine launched in the UK	Apr. 05	CF

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet

February 01, 2024 at 11:26 am EST

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

86.89 EUR

Average target price

107.5 EUR

Spread / Average Target

+23.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	-3.20%	116B
ELI LILLY AND COMPANY	+24.60%	654B
NOVO NORDISK A/S	+24.08%	552B
JOHNSON & JOHNSON	-5.63%	356B
MERCK & CO., INC.	+15.37%	319B
ABBVIE INC.	+7.38%	295B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	206B
PFIZER, INC.	-9.69%	147B
AMGEN INC.	-6.63%	144B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : UBS reiterates its Neutral rating

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals